Please enable Javascript
Advanced Renal Cell Carcinoma
Advertisement
FDA Grants Priority Review to Belzutifan in Previously Treated Advanced RCC
Zachary Bessette
Advanced Renal Cell Carcinoma
|
September 20, 2023
The FDA has accepted for priority review the sNDA for belzutifan in patients who were previously treated for advanced RCC.
Read More
Postimmunotherapy Nephrectomy Provides Improved PFS in Patients With aRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
September 8, 2023
Improved PFS was associated with negative surgical margins and no 30-day surgical complications, plus pathologic downstaging.
Read More
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Hans Hammers, MD, PhD
Renal Cell Carcinoma
|
September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Read More
LITESPARK-005: Belzutifan Improves PFS in Previously Treated Patients With Advanced RCC
Zachary Bessette
Advanced Renal Cell Carcinoma
|
August 22, 2023
Belzutifan improves PFS in adult patients with advanced RCC who have progressed on previous PD-1/PD-L1 or VEGF-TKI therapies.
Read More
Duration of Exposure to Antiangiogenics in ccRCC Treated With Nivolumab
Emily Menendez
Advanced Renal Cell Carcinoma
|
August 11, 2023
Researchers investigated the impact of duration of exposure to antiangiogenics on immunotherapy outcomes in metastatic ccRCC.
Read More
ICI Combinations Provide More Benefit for Female Patients With mRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
July 28, 2023
Researchers from the Mayo Clinic assessed the efficacy of ICI combination therapy as a first-line mRCC treatment.
Read More
Dr. Jérémie Calais on a Novel Radiotracer That Detects, Differentiates Renal Cell Carcinomas
Jérémie Calais, MD, MSc
SNMMI 2023
|
July 25, 2023
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
View More
Outcomes of Cytoreductive Nephrectomy After IO Regimens in mRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
July 19, 2023
Researchers summarized the survival outcomes of patients with mRCC treated with CN after IO-based perioperative treatments.
Read More
CLEAR Study 4-Year Follow-up Supports Use of Lenvatinib and Pembrolizumab for aRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
July 19, 2023
Research presented at KCRS23 characterized patients with an OR in the lenvatinib plus pembrolizumab arm of the CLEAR study.
Read More
Time to Metastasis in Patients With Synchronous and Metachronous mRCC Treated With ICIs
Emily Menendez
Advanced Renal Cell Carcinoma
|
July 19, 2023
At KCRS23, researchers presented their data on the differences in clinical outcomes in patients with synchronous and metachro
Read More
Dr. Thomas Hutson on Long-Term Durable Response After 4 Years Follow-Up in the CLEAR Study
Thomas Hutson, DO, PharmD, FACP
ASCO 2023
|
July 17, 2023
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
View More
Dr. Thomas Hutson on Conventional and Novel Combination Therapies for First-Line Advanced RCC
Thomas Hutson, DO, PharmD, FACP
ASCO 2023
|
July 17, 2023
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
View More
Anti-PD-L1 Combinations Show Reduced Risk of Progression for mRCC Compared With Sunitinib
Emily Menendez
Advanced Renal Cell Carcinoma
|
July 10, 2023
The IMmotion150, IMmotion151, and JAVELIN Renal 101 trials were assessed for OS, PFS, and ORR of anti-PD-L1 combinations.
Read More
Dr. Laurence Albiges on Results of Arm B5 of KEYMAKER-U03B for Belzutifan Plus Lenvatinib in accRCC
Laurence Albiges, MD, PhD
ASCO 2023
|
July 6, 2023
Dr. Albiges details the KEYMAKER-U03B study, outcomes for patients in arm B5, and next lines of research for belzutifan.
View More
Drs. Rini, Wallis on a 5-Year Analysis of KEYNOTE-426 for Advanced Clear Cell RCC
Brian Rini, MD, FASCO
ASCO 2023
|
June 5, 2023
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
View More
CONTACT-03: Primary PFS Analysis of Atezolizumab Plus Cabozantinib After Progression in mRCC
Zachary Bessette
ASCO 2023
|
June 5, 2023
Updated PFS data was presented for the first phase 3, randomized trial to test the benefit of ICI rechallenge in mRCC.
Read More
CBM588 Plus Cabozantinib and Nivolumab for Metastatic RCC
Zachary Bessette
ASCO 2023
|
June 4, 2023
CBM588 may improve clinical outcomes for patients with mRCC when combined with the cabozantinib plus nivolumab.
Read More
Patients With mRCC Prefer Complete Response in Treatment Options
Emily Menendez
ASCO 2023
|
May 31, 2023
A study from ASCO 2023 surveyed patients to determine how they prioritize their treatment selection for mRCC.
Read More
Nivolumab Plus Cabozantinib Improves HRQoL for Patients With aRCC
Emily Menendez
ASCO 2023
|
May 31, 2023
Researchers conducted an exploratory follow-up analysis of HRQoL in treament with nivolumab plus cabozantinib vs sunitinib.
Read More
Triplet Combination Appears Promising in Patients With RCC and Variant Histologies
Zachary Bessette
ASCO 2023
|
May 26, 2023
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
Read More
Load More
Advertisement
Advertisement
Advertisement